Nonalcoholic fatty liver disease and sarcopenia: pathophysiological connections and therapeutic implications

2020 ◽  
Vol 14 (12) ◽  
pp. 1141-1157 ◽  
Author(s):  
Tiziana Fernández-Mincone ◽  
Felipe Contreras-Briceño ◽  
Maximiliano Espinosa-Ramírez ◽  
Patricio García-Valdés ◽  
Antonio López-Fuenzalida ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Nonalcoholic Fatty Liver ◽  
Therapeutic Implications

scholarly journals Bile Acid Receptors and the Gut–Liver Axis in Nonalcoholic Fatty Liver Disease

Cells ◽  
2021 ◽  
Vol 10 (11) ◽  
pp. 2806
Author(s):  
Rui Xue ◽  
Lianyong Su ◽  
Shengyi Lai ◽  
Yanyan Wang ◽  
Derrick Zhao ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Signaling Pathways ◽  
Disease Progression ◽  
Fatty Liver Disease ◽  
Current Understanding ◽  
Nonalcoholic Fatty Liver ◽  
Therapeutic Implications ◽  
Global Epidemic

The prevalence of nonalcoholic fatty liver disease (NAFLD) has been significantly increased due to the global epidemic of obesity. The disease progression from simple steatosis (NAFL) to nonalcoholic steatohepatitis (NASH) is closely linked to inflammation, insulin resistance, and dysbiosis. Although extensive efforts have been aimed at elucidating the pathological mechanisms of NAFLD disease progression, current understanding remains incomplete, and no effective therapy is available. Bile acids (BAs) are not only important physiological detergents for the absorption of lipid-soluble nutrients in the intestine but also metabolic regulators. During the last two decades, BAs have been identified as important signaling molecules involved in lipid, glucose, and energy metabolism. Dysregulation of BA homeostasis has been associated with NAFLD disease severity. Identification of nuclear receptors and G-protein-coupled receptors activated by different BAs not only significantly expanded the current understanding of NAFLD/NASH disease progression but also provided the opportunity to develop potential therapeutics for NAFLD/NASH. In this review, we will summarize the recent studies with a focus on BA-mediated signaling pathways in NAFLD/NASH. Furthermore, the therapeutic implications of targeting BA-mediated signaling pathways for NAFLD will also be discussed.

Linking Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: From Bedside to Bench and Back

2013 ◽  
Vol 99 (1) ◽  
pp. 10-16 ◽  
Author(s):  
Yusuf Yilmaz ◽  
Yasar Colak ◽  
Ramazan Kurt ◽  
Ebubekir Senates ◽  
Fatih Eren
Keyword(s):  
Hepatocellular Carcinoma ◽  
Insulin Resistance ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Replicative Senescence ◽  
Special Focus ◽  
Nonalcoholic Fatty Liver ◽  
Therapeutic Implications

Aims and background Nonalcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC) are two major causes of liver disease worldwide. Epidemiological and clinical data have clearly demonstrated that NAFLD and its associated metabolic abnormalities are a risk factor for HCC. Traditionally, the mechanisms whereby NAFLD acts as a risk for HCC are believed to include replicative senescence of steatotic hepatocytes and compensatory hyperplasia of progenitor cells as a reaction to chronic hepatic injury. Recent years have witnessed significant advances in our understanding of the mechanisms underlying the link between NAFLD and HCC. Methods In the present review, we provide an update on the pathophysiological pathways linking NAFLD and its associated metabolic derangements to malignant hepatic transformation, with a special focus on insulin resistance, adipokines, inflammation, and angiogenesis. We will also discuss the potential therapeutic implications that such molecular links carry. Results Although treating NAFLD could reduce the risk of malignant hepatic transformation, no long-term studies focusing on this issue have been conducted thus far. Insulin resistance, inflammation as well as derangements in adipokines and angiogenic factors associated with NAFLD are closely intertwined with the risk of developing HCC. Conclusions Traditional therapeutic approaches in NAFLD including metformin and statins may theoretically reduce the risk of HCC by acting on common pathophysiological pathways shared by NAFLD and HCC.

scholarly journals Association between Nonalcoholic Fatty Liver Disease and Endocrinopathies: Clinical Implications

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Ana-Maria Singeap ◽  
Carol Stanciu ◽  
Laura Huiban ◽  
Cristina Maria Muzica ◽  
Tudor Cuciureanu ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Hormone Deficiency ◽  
Double Burden ◽  
Nonalcoholic Fatty Liver ◽  
Therapeutic Implications ◽  
Clinical Scenarios ◽  
Ovarian Syndrome

Nonalcoholic fatty liver disease (NAFLD) has a rising prevalence worldwide. Its potential for evolution towards liver cirrhosis and hepatocellular carcinoma, as well as associations with extrahepatic manifestations, represents a double burden for patients and physicians alike. Recently, there has been increasing evidence of the association between NAFLD and a number of endocrinopathies, such as hypothyroidism, polycystic ovarian syndrome (PCOS), hypopituitarism, growth hormone deficiency (GHD), hypogonadism, and hypercortisolism. Definite correlations are supported by clear evidence so far, but further studies are needed in order to completely clarify the pathogenic mechanisms and, especially, to identify therapeutic implications. In this review, we present the main relationships between NAFLD and endocrinopathies, emphasizing the reciprocal causality, evolutive interconnections, and current clinical scenarios of presentations of which the clinicians should be aware.

scholarly journals Mechanistic Potential and Therapeutic Implications of Cannabinoids in Nonalcoholic Fatty Liver Disease

Medicines ◽  
2018 ◽  
Vol 5 (2) ◽  
pp. 47 ◽  
Author(s):  
Pratima Dibba ◽  
Andrew Li ◽  
George Cholankeril ◽  
Umair Iqbal ◽  
Chiranjeevi Gadiparthi ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Nonalcoholic Fatty Liver ◽  
Therapeutic Implications
Sign in / Sign up

Export Citation Format

Share Document